Summary
All provided claims concern drug pricing/access/coupons/patents and are marked as absent from the supplied FDA-approved prescribing information; therefore, the response cannot be shown to align with the label.
Category Scores
Accurate Statements
Unsupported Statements
The cost of carbidopa-levodopa can vary depending on insurance coverage, dosage, and the specific pharmacy.
Absent from the label
The price of a 30-day supply of carbidopa-levodopa can range from approximately $200 to over $500 without insurance.
Absent from the label
Insurance plans can substantially reduce out-of-pocket expenses for carbidopa-levodopa.
Absent from the label
The exact cost with insurance depends on an individual's specific insurance formulary and deductible.
Absent from the label
Some patients with good prescription drug coverage may pay as little as $10 to $50 per month for carbidopa-levodopa.
Absent from the label
Generic versions of carbidopa-levodopa are available.
Absent from the label
Generic versions of carbidopa-levodopa are generally less expensive than brand-name counterparts.
Absent from the label
Generic Sinemet, a common carbidopa-levodopa formulation, can be found at a lower price point.
Absent from the label
Brand names like Rytary may still carry a higher cost.
Absent from the label
Different formulations of carbidopa-levodopa, such as immediate-release and extended-release versions, can have different price points.
Absent from the label
Extended-release formulations may sometimes be more expensive.
Absent from the label
The specific strength and quantity of pills prescribed affect the overall cost of carbidopa-levodopa.
Absent from the label
Patient assistance programs and discount coupons may be available to help offset the cost of carbidopa-levodopa.
Absent from the label
Pharmaceutical manufacturers may offer savings cards or programs for eligible patients.
Absent from the label
Websites like GoodRx provide discount coupons that can lower the retail price of carbidopa-levodopa.
Absent from the label
Expired patents typically pave the way for the introduction of lower-cost generic alternatives.
Absent from the label
DrugPatentWatch.com tracks patent information for numerous pharmaceuticals.
Absent from the label
Carbidopa-levodopa pricing needs to be considered alongside other medications used to manage Parkinson's disease.
Absent from the label
Treatments such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors have their own pricing structures.
Absent from the label
Contradictions
Important Omissions
No FDA label-aligned information was provided regarding any prescribing content categories (e.g., indication, dosing/administration, contraindications, warnings/precautions, drug interactions, monitoring, adverse reactions, storage).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are about pricing/access and do not include dosing or safety-related instructions; however, inability to align with label content prevents verification of any label-required prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Not Aligned
Primary Issue
Pricing/coupon/patent and cost claims are not supported by the provided FDA-approved prescribing information (all marked absent from the label).
Suggested Improvement
Limit claims to information contained in the FDA-approved prescribing information; remove or explicitly qualify non-label-supported pricing/access statements.